Patents by Inventor Songqing Na

Songqing Na has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES
    Publication number: 20240100176
    Abstract: The present disclosure provides human interleukin 4 receptor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of inflammatory diseases, such as type 2 inflammatory diseases.
    Type: Application
    Filed: May 31, 2023
    Publication date: March 28, 2024
    Inventors: Shane Krummen Atwell, Joshua R Clayton, Yiqing Feng, Maya Rachel Karta, Donmienne Doen Mun Leung, Songqing Na, Kristin Paige Newburn, Laura Anne Pelletier, Diana Isabel Ruiz, David John Stokell, Jacqueline M Wurst, Scott Paul Bauer
  • HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES
    Publication number: 20240082414
    Abstract: The present disclosure provides human tumor necrosis factor alpha antibody glucocorticoid receptor agonist conjugates and methods of using the conjugates for the treatment of autoimmune and inflammatory diseases.
    Type: Application
    Filed: May 5, 2023
    Publication date: March 14, 2024
    Inventors: Grace Chao, Joshua R Clayton, Jordan Scott Crampton, Yiqing Feng, Donmienne Doen Mun Leung, Songqing Na, Kristin Paige Newburn, Scott Charles Potter, Bharathi Ramamurthy, David John Stokell, Jacqueline M. Wurst, Jianghuai Xu
  • Human interleukin-4 receptor alpha antibodies
    Patent number: 11891441
    Abstract: The present disclosure relates to antibodies that specifically bind human IL-4R?, compositions comprising such IL-4R? antibodies, and methods of using such IL-4R? antibodies.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: February 6, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Shane Krummen Atwell, Yiqing Feng, Maya Rachel Karta, Donmienne Leung, Songqing Na, Diana Isabel Ruiz, David John Stokell, Laura Anne Pelletier
  • HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODIES
    Publication number: 20230192837
    Abstract: The present disclosure relates to antibodies that specifically bind soluble and membrane forms of human TNF?, compositions comprising such TNF? antibodies, and methods of using such TNF? antibodies and compositions.
    Type: Application
    Filed: November 10, 2022
    Publication date: June 22, 2023
    Inventors: Grace Chao, Yiqing Feng, Donmienne Doen Mun Leung, Songqing Na, Bharathi Ramamurthy, Jianghuai Xu
  • Anti-human CD19 antibodies
    Patent number: 11623956
    Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: April 11, 2023
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
  • HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODIES
    Publication number: 20230064378
    Abstract: The present disclosure relates to antibodies that specifically bind human IL-4R?, compositions comprising such IL-4R? antibodies, and methods of using such IL-4R? antibodies.
    Type: Application
    Filed: August 5, 2022
    Publication date: March 2, 2023
    Inventors: Shane Krummen ATWELL, Yiqing FENG, Maya Rachel KARTA, Donmienne LEUNG, Songqing NA, Diana Isabel RUIZ, David John STOKELL, Laura Anne Pelletier
  • ANTI-HUMAN CD19 ANTIBODIES
    Publication number: 20210269520
    Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.
    Type: Application
    Filed: February 22, 2021
    Publication date: September 2, 2021
    Inventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
  • ANTI-TNF- / ANTI-IL-23 IgG BISPECIFIC ANTIBODIES
    Publication number: 20190040156
    Abstract: IgG bispecific antibodies are provided that bind tumor necrosis factor alpha (TNF?) and the p19 subunit of interleukin-23 (IL-23p19) and are characterized as having high affinity and simultaneous neutralizing properties to both TNF? and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, and Hidradenitis suppurativa.
    Type: Application
    Filed: July 26, 2018
    Publication date: February 7, 2019
    Inventors: Stephen J Demarest, Songqing Na, Jeffrey S Boyles, Qing Chai
  • Anti-TNF-/anti-IL-23 bispecific antibodies
    Patent number: 9718884
    Abstract: Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNF?) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNF? and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: August 1, 2017
    Assignee: Eli Lilly and Company
    Inventors: Rohn L Millican, Jr., Neungseon Seo, Songqing Na, Catherine B. Beidler
  • ANTI-TNF- / ANTI-IL-23 BISPECIFIC ANTIBODIES
    Publication number: 20160122429
    Abstract: Bispecific antibodies are provided that bind Tumor Necrosis Factor alpha (TNF?) and the p19 subunit of Interleukin-23 (IL-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both TNF? and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Axial Spondyloarthropathy, Rheumatoid Arthritis and Psoriatic Arthritis.
    Type: Application
    Filed: November 3, 2015
    Publication date: May 5, 2016
    Inventors: Rohn L Millican, Neungseon Seo, Songqing Na, Catherine B. Beidler
  • Novel proteins and their uses
    Publication number: 20060142558
    Abstract: The present invention provides nucleic acid sequences encoding novel human proteins. These novel nucleic acids are useful for constructing the claimed DNA vectors and host cells of the invention and for preparing the claimed nucleic acids, recombinant proteins and antibodies that are useful in the claimed methods and medical uses.
    Type: Application
    Filed: July 23, 2003
    Publication date: June 29, 2006
    Inventors: Songqing Na, Douglas Perkins
  • Treating b-cell mediated diseases by modulating dr6 activity
    Publication number: 20050069540
    Abstract: Novel methods are provided for the treatment or prevention of B cell mediated conditions in a mammal that comprise administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising at least one DR6 agonist or DR6 antagonist.
    Type: Application
    Filed: December 10, 2002
    Publication date: March 31, 2005
    Inventors: Jinqi Liu, Songqing Na, Ho Yeong, Derek Yang
  • Novel polypeptide analogs and fusions and their methods of use
    Publication number: 20040236088
    Abstract: Novel polypeptide analogs and fusion proteins of a transmembrane protein, LP276, are provided. Vectors and host cells directed to these polypeptides are provided. Additionally, methods of use are provided for the treatment or prevention of allergic autoimmune diseases, type 1 diabetes, inflammation, immunodeficiencies, cancers, and infectious diseases by administering an LP276 polypeptide, analogs and fusion proteins thereof to a patient in need of such therapy.
    Type: Application
    Filed: January 15, 2004
    Publication date: November 25, 2004
    Inventors: Josef Georg Heuer, Songqing Na, Angela Jeannine Okragly, Weijia Ou
  • Therapeutic applications of mFLINT polypeptides
    Publication number: 20040167074
    Abstract: Mature FLINT protein (mFLINT) binds FasL and LIGHT, and prevents FasL-Fas interaction. mFLINT inhibits FasL-Fas-mediated apoptotic and proinflammatory activity, and is useful in treating disorders associated with abnormal apoptosis and inflammation. The invention provides the amino acid and nucleotide sequences of FLINT and mature FLINT. The preparation and characterization of transgenic animals that express FLINT is disclosed. Therapeutic compositions and methods of treatment utilizing mFLINT also are provided.
    Type: Application
    Filed: March 4, 2004
    Publication date: August 26, 2004
    Inventors: Thomas Frank Bumol, Shenshen Dou, Andrew Lawrence Glasebrook, Songqing Na, Ho Yeong Song, Steven Harold Zuckerman
  • Treating t-cell mediated diseases by modulating dr6 activity
    Publication number: 20040043022
    Abstract: Novel methods are provided for the treatment or prevention of T cell mediated conditions in a mammal that comprise administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising at least one DR6 agonist or DR6 antagonist.
    Type: Application
    Filed: October 16, 2002
    Publication date: March 4, 2004
    Inventors: Josef Georg Heuer, Jinqi Liu, Songqing Na, Ho Yeong Song, Derek Di Yang
  • Treating musculoskeletal disorders using lp85 and analogs thereof
    Publication number: 20030100502
    Abstract: The invention provides methods for treating or preventing osteoporosis, osteopenia, sarcopenia, arthritis, tissue atrophy, wound healing, traumatized connective tissues, grafted connective tissues, and/or transplanted organs in a mammal which comprise the administration of a therapeutically effective amount of a pharmaceutical composition comprising a LP85 polypeptide or LP85 analog.
    Type: Application
    Filed: October 23, 2002
    Publication date: May 29, 2003
    Inventors: John Michael Beals, Patricia Ann Gonzalez-DeWhitt, Lisa Janine Hammond, Jirong Lu, Songqing Na, Eric Wen Su, Derrick Ryan Witcher